OA18659A - Therapeutic Agent for Frontal Lobe Dysfunction. - Google Patents
Therapeutic Agent for Frontal Lobe Dysfunction. Download PDFInfo
- Publication number
- OA18659A OA18659A OA1201700372 OA18659A OA 18659 A OA18659 A OA 18659A OA 1201700372 OA1201700372 OA 1201700372 OA 18659 A OA18659 A OA 18659A
- Authority
- OA
- OAPI
- Prior art keywords
- cognitive impairment
- disease
- lewy body
- body disease
- pharmaceutically acceptable
- Prior art date
Links
- 210000001652 Frontal Lobe Anatomy 0.000 title claims abstract description 29
- 230000004064 dysfunction Effects 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims abstract description 106
- 206010057668 Cognitive disease Diseases 0.000 claims abstract description 100
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 208000009829 Lewy Body Disease Diseases 0.000 claims abstract description 72
- 206010067889 Dementia with Lewy body Diseases 0.000 claims abstract description 50
- 206010061536 Parkinson's disease Diseases 0.000 claims abstract description 41
- 201000009457 movement disease Diseases 0.000 claims abstract description 23
- 230000037326 chronic stress Effects 0.000 claims abstract description 17
- 230000001225 therapeutic Effects 0.000 claims abstract description 16
- 201000011240 frontotemporal dementia Diseases 0.000 claims abstract description 12
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims abstract description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 30
- 208000001652 Memory Disorders Diseases 0.000 claims description 19
- 210000002442 Prefrontal Cortex Anatomy 0.000 claims description 18
- 229960003638 dopamine Drugs 0.000 claims description 15
- 206010070246 Executive dysfunction Diseases 0.000 claims description 11
- 230000019771 cognition Effects 0.000 claims description 11
- 230000035943 smell Effects 0.000 claims description 11
- 230000000069 prophylaxis Effects 0.000 claims description 9
- 230000000007 visual effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 26
- 239000011780 sodium chloride Substances 0.000 abstract description 9
- 150000003839 salts Chemical class 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 description 18
- 230000005021 gait Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- 210000004744 fore-foot Anatomy 0.000 description 14
- 210000000548 hind-foot Anatomy 0.000 description 14
- 230000006399 behavior Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000003920 cognitive function Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000004556 Brain Anatomy 0.000 description 9
- 230000002269 spontaneous Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000003291 dopaminomimetic Effects 0.000 description 6
- -1 inorganic acid salts Chemical class 0.000 description 6
- 230000006403 short-term memory Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000003542 behavioural Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 4
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 208000001089 Multiple System Atrophy Diseases 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000001149 cognitive Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000002683 Foot Anatomy 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- DIVDFFZHCJEHGG-UHFFFAOYSA-N Oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 3
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000003802 alpha-Synuclein Human genes 0.000 description 3
- 108090000185 alpha-Synuclein Proteins 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 229960003829 Desipramine Hydrochloride Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 2
- 229960002748 Norepinephrine Drugs 0.000 description 2
- 208000003715 Parkinsonian Disorders Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 229960002275 Pentobarbital Sodium Drugs 0.000 description 2
- 229940076279 Serotonin Drugs 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960003692 aminobutyric acid Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XAEWZDYWZHIUCT-UHFFFAOYSA-N desipramine hydrochloride Chemical compound [H+].[Cl-].C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 XAEWZDYWZHIUCT-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229940116317 potato starch Drugs 0.000 description 2
- 230000002360 prefrontal Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QGMRQYFBGABWDR-OGFXRTJISA-M sodium;5-ethyl-5-[(2R)-pentan-2-yl]pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC[C@@H](C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-OGFXRTJISA-M 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000003356 synucleinopathy Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Chemical class 0.000 description 1
- 229960002449 Glycine Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N Istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- 229950009028 Istradefylline Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 210000004558 Lewy Bodies Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 210000001577 Neostriatum Anatomy 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 208000001292 Olivopontocerebellar Atrophy Diseases 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 210000000063 Presynaptic Terminals Anatomy 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000003755 Striatonigral Degeneration Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108020003835 TX1 Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001713 cholinergic Effects 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical class 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004255 neuroglia Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 230000002474 noradrenergic Effects 0.000 description 1
- 201000003497 olivopontocerebellar atrophy Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004036 social memory Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
The present invention provides a therapeutic and/or prophylactic agent for, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like, which contains a compound represented by the formula (I)
Description
DESCRIPTION Title of the Invention: THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFONCTION Technical Field
The présent invention relates to a therapeutic and/or prophylactic agent for, for exemple, frontal lobe dysfunction (for example, cognitive impairment (for exemple, cognitive impeirment in Parkinson's disease (for example, executive dysfunction, memory disorder (particularly short term memory disorder), impairment in visual spatial cognition, smell disturbance and the like), cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for exemple, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like. Background Art
The prefrontal cortex of the frontal lobe of the brain is responsible for cognitive functions (for example, compréhension, judgment, calculation ability, orientation, executive function and the like). Neurotransmitters such as dopamine, serotonin, norepinephrine, gamma-aminobutyric acid and the like are involved in the function of prefrontal cortex, and shortage of these substances causes cognitive impairment. For example, it has been reported that décliné in dopamine function and décliné in cognitive function are correlated in elderly people (American Journal of Psychiatry 155:3, p.344 (1998)). It has also been reported that décliné in dopamine function in the prefrontal cortex is possibly related to cognitive impairment i i in Parkinson's disease and cognitive impairment caused by i chronic stress (Archives of Neurology, 57, p.470 (2000); The l
Journal of Neuroscience, 20(4), p.1568 (2000)). It has been reported that dopamine is déficient in the prefrontal cortex of Parkinson's disease patients with dementia and dementia with lewy bodies patients (Neurology, 74, p.885 (2010)).
α-Synuclein is a protein présent in large amounts in the intracérébral presynaptic terminal, and involved in synaptic plasticity and neurotransmission (Journal of Chemical Neuroanatomy, 42, p.242 (2011)). α-Synucleinopathy is a generic term for neurodegenerative diseases characterized by accumulation and formation of aggregation of α-synuclein, and examples thereof comprise Lewy body diseases (for example, Parkinson's disease dementia, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like), multiple System atrophy (for example, olivopontocerebellar atrophy, striatonigral degeneration, Shy-Drager syndrome and the like) and the like.
In Lewy body disease, Lewy bodies containing a-synuclein aggregates as a main component are found in nerve cells and, in multiple System atrophy, α-synuclein-positive inclusions body are found in glial cells. Varions symptoms such as parkinsonism, cognitive impairment, autonomie symptom, cerebellar ataxia and the like manifest themselves depending on the level of distribution of these pathologies (Parkinsonism and related disorders, 20S1, p.S62 (2014)).
The cognitive impairment in Lewy body diseases is considered to involve dopaminergic and cholinergic hypofunctions in the frontal lobe (Brain, 137, p.2493 (2014); Neurology, 74, p.885 (2010)). The prefrontal cortex of the frontal lobe in the brain is a région responsible for cognitive functions (for example, compréhension, judgment, calculation ability, orientation, executive function and the like). Neurotransmitters such as dopamine, serotonin, norepinephrine, gamma-aminobutyric acid and the like are involved in the function of prefrontal cortex, and shortage of these substances causes cognitive impairment.
On the other hand, as regards the relationship between adenosine A2a receptor and cognitive function, it is known that adenosine A2a receptor déficient mice show increased working memory (non-patent document 1). A triazolotriazine dérivative having an adenosine A2a receptor antagonistic activity is known to improve short-term social memory disorders in hypertension rats (non-patent document 2). Furthermore, an adenosine A2a receptor antagonist, istradefylline, is known to hâve a suppressive activity on neurodegeneration (for example, patent document 1), an improving effect on cognitive impairment in Parkinson's disease (non-patent document 3) and the like.
A compound represented by the formula (I) is known to hâve affinity for adenosine A2a receptors and has a therapeutic effect on Parkinson's disease (patent document 2). Also, this compound is known to be useful as a therapeutic and/or prophylactic agent for movement disorders (patent document 3) .
N
[Prior Art Documents] patent documents
[patent document 1] WO 99/12546
[patent document 2] WO 2005/063743
[patent document 3] WO 2010/126082 non-patent documents
[non-patent document 1] Brain Research, 2009, vol. 1303, p.74
[non-patent document 2] Behavioural Brain Research, 2005, vol.
159, p.197
[non-patent document 3] Psychopharmacology, 2013, vol. 230, p.345
SUMMARY OF THE INVENTION
Problems to be Solved by the Invention
An object of the présent invention is to provide a therapeutic and/or prophylactic agent for, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease (for example, executive dysfunction, memory disorder (particularly short term memory disorder), impairment in Visual spatial cognition, smell disturbance and the like), cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for example, cognitive impairment in Parkinson'’s disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like.
Means of Solving the Problems
The présent invention relates to the following (1) - (52).
(1) A therapeutic and/or prophylactic agent for frontal lobe dysfunction, comprising a compound represented by the formula (D :
(1) or a pharmaceutically acceptable sait thereof, as an active ingrédient.
(2) The agent according to (1), wherein the frontal lobe dysfunction is cognitive impairment.
(3) The agent according to (2), wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.
(4) The agent according to (2), wherein the cognitive impairment is cognitive impairment in Parkinson's disease.
(5) The agent according to (4), wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in visual spatial cognition or smell disturbance.
(6) The agent according to (2), wherein the cognitive impairment is cognitive, impairment caused by. chronic stress.
(7) The agent according to (2) , wherein the cognitive ' impairment is dementia with lewy bodies. . . .
(8) The agent according to (1), wherein the frontal.lobe dysfunction is cognitive impairment due to a décliné in dopamine function in the médial prefrontal cortex.
(9) A therapeutic and/or prophylactic agent for Lewy body disease, comprising a compound represented by the formula (I) :
(I) or a pharmaceutically acceptable sait thereof, as an active ingrédient.
(10) The agent according to (9), wherein the Lewy body disease is cognitive impairment in Parkinson's disease.
(11) The agent according to (9), wherein the Lewy body disease is diffuse Lewy body disease.
(12) The agent according to (9), wherein the Lewy body disease is dementia with lewy bodies.
(13) The agent according to (9), wherein the Lewy body disease is movement disorder associated with Lewy body disease.
(14) A method for the treatment and/or prophylaxis of frontal lobe dysfunction, comprising a step of administering an effective amount of a compound represented by the formula (I):
(D or a pharmaceutically acceptable sait thereof.
(15) The method according to (14), wherein the frontal lobe dysfunction is cognitive impairment.
(16) The method according to (15), wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.
(17) The method according to (15), wherein the cognitive impairment is cognitive impairment in Parkinson's disease.
(18) The method according to (17), wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in visual spatial cognition or smell disturbance.
(19) The method according to (15), wherein the cognitive impairment is cognitive impairment caused by chronic stress.
(20) The method according to (15), wherein the cognitive impairment is dementia with lewy bodies.
(21) The method according to (14), wherein the frontal lobe dysfunction is cognitive impairment due to a décliné in dopamine function in the médial prefrontal cortex.
(22) A method for the treatment and/or prophylaxis of Lewy body disease, comprising a step of administering an effective amount of a compound represented by the formula (I):
(I) or a pharmaceutically acceptable sait thereof.
(23) The agent according to (22), wherein the Lewy body disease is cognitive impairment in Parkinson's disease.
(24) The agent according to (22), wherein the Lewy body disease is diffuse Lewy body disease.
(25) The agent according to (22), wherein the Lewy body disease is dementia with lewy bodies.
(26) The agent according to (22), wherein the Lewy body disease is movement disorder associated with Lewy body disease.
(27) A compound represented by the formula (I):
(l) or a pharmaceutically acceptable sait thereof, for use in the treatment and/or prophylaxis of frontal lobe dysfunction.
(28) The compound or the pharmaceutically acceptable sait thereof according to (27), wherein the frontal lobe dysfunction is cognitive impairment.
(29) The compound or the pharmaceutically acceptable sait thereof according to (28), wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.
(30) The compound or the pharmaceutically acceptable sait thereof according to (28), wherein the cognitive impairment is cognitive impairment in Parkinson's disease.
(31) The compound or the pharmaceutically acceptable sait thereof according to (30), wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in visual spatial cognition or smell disturbance.
(32) The compound or the pharmaceutically acceptable sait thereof according to (28), wherein the cognitive impairment is cognitive impairment caused by chronic stress.
(3.3) The compound or the pharmaceutically acceptable sait thereof according to (28), wherein the cognitive impairment is dementia with lewy bodies.
(34) The compound or the pharmaceutically acceptable sait thereof according to (27), wherein the frontal lobe dysfunction is cognitive impairment due to a décliné in dopamine function in the médial prefrontal cortex.
(35) A compound represented by the formula (I):
(l) or a pharmaceutically acceptable sait thereof, for use in the treatment and/or prophylaxis of Lewy body disease.
(36) The compound or the pharmaceutically acceptable sait thereof according to (35), wherein the Lewy body disease is cognitive impairment in Parkinson's disease.
(37) The compound or the pharmaceutically acceptable sait thereof according to (35), wherein the Lewy body disease is diffuse Lewy body disease.
(38) The compound or the pharmaceutically acceptable sait thereof according to (35), wherein the Lewy body disease is dementia with lewy bodies.
(39) The compound or the pharmaceutically acceptable sait thereof according to (35), wherein the Lewy body disease is movement disorder associated with Lewy body disease.
(40) Use of a compound represented by the formula (I):
(l) or a pharmaceutically acceptable sait thereof, for the manufacture of a therapeutic and/or prophylactic agent for frontal lobe dysfunction.
(41) The use according to (40), wherein the frontal lobe dysfunction is cognitive impairment.
(42) The use according to (41), wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chrome stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.
(43) The use according to (41), wherein the cognitive impairment is cognitive impairment in Parkinson's disease.
(44) The use according to (43), wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in Visual spatial cognition or smell disturbance.
(45) The use according to (41), wherein the cognitive impairment is cognitive impairment caused by chronic stress.
(46) The use according to (41), wherein the cognitive w impairment is dementia with lewy bodies.
(47) The use according to (40), wherein the frontal lobe dysfunction is cognitive impairment due to a décliné in dopamine function in the media! prefrontal cortex.
(48) Use of a compound represented by the formula (I):
or a pharmaceutically acceptable sait thereof, for the manufacture of a therapeutic and/or prophylactic agent for Lewy body disease.
(49) The use according to (48), wherein the Lewy body disease is cognitive impairment in Parkinson's disease.
(50) The use according to (48), wherein the Lewy body disease is diffuse Lewy body disease.
(51) The use according to (48), wherein the Lewy body disease is dementia with lewy bodies.
(52) The use according to (48), wherein the Lewy body disease is movement disorder associated with Lewy body disease.
Effect of the Invention
According to the présent invention, a therapeutic and/or prophylactic agent and the like for frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease (for example, executive dysfunction, memory disorder (particularly short term memory disorder), impairment in visuai spatial cognition, smell disturbance and the like), dementia with lewy bodies, cognitive impairment caused by chronic stress, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like, which comprises a compound represented by the formula (I):
(D or a pharmaceutically acceptable sait thereof, as an active ingrédient are provided.
The therapeutic and/or prophylactic agent of the présent invention can be utilized for the treatment and/or prophylaxis of, for example, diseases such as frontal lobe dysfunction and the like, among others, cognitive impairment due to a décliné in dopamine function in the médial prefrontal cortex.
Mode for Carrying out the Invention
Examples of the frontal lobe dysfunction in the présent invention include cognitive impairment (for example, cognitive impairment in Parkinson's disease (for example, executive dysfunction, memory disorder (particularly short term memory disorder), impairment in visuai spatial cognition, smell disturbance and the like), cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like. These diseases are related to a décliné in dopamine function in the médial prefrontal cortex.
Examples of the Lewy body disease in the présent invention include cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like.
In the following, a compound represented by the formula.
(I) is sometimes to be referred to as compound (I).
A pharmaceutically acceptable sait of compound (I). · encompasses, for example, a pharmaceutically acceptable acid addition sait, a métal sait, an ammonium sait, an organic amine addition sait, an amino acid addition sait and the like.
Examples of the pharmaceutically acceptable acid addition sait of compound (I) include inorganic acid salts such as hydrochloride, hydrobromide, nitrate, sulfate, phosphate and the like, organic acid salts such as acetate, oxalate, maleate, . fumarate, citrate, benzoate, methanesulfonate and the like, and the like. Examples of the pharmaceutically acceptable métal sait include alkali métal salts such as sodium sait, potassium sait and the like, alkaline earth métal salts such as magnésium sait, calcium sait and the like, aluminum sait, zinc sait and the like. Examples of the pharmaceutically acceptable ammonium sait include salts of ammonium, tétraméthylammonium and the like, examples of the pharmaceutically acceptable organic amine addition sait include addition salts with morpholine, piperidine and the like, and examples of the pharmaceutically acceptable amino acid addition sait include addition salts of lysine, glycine, phenylalanine, aspartic acid, glutamic acid and the like.
Compound (I) or the pharmaceutically acceptable salts thereof to be used in the présent invention can be produced, for example, by the method described in Example 504 of WO 2005/063743.
When a sait of compound (I) is desired and compound (I) is obtained in the form of a sait, it only needs to be directly purified, or when it is obtained as a free form, compound (I) . is dissolved or suspended in a suitable solvent, and an acid, or base is added to form a sait, which is isolated and purified.
Also, compound (I) or a pharmaceutically acceptable sait i
thereof may be présent in the form of an adduct with water or varions solvents, and such adduct can also be used as the therapeutic and/or prophylactic agent of the présent invention.
Next, the représentative pharmacological effect of .
compound (I) is concretely explained by way of Experimental Examples. [Experimental Example 1] Effect of compound (I) in object récognition test using médial prefrontal dopaminergic terminallesioned rat
The object récognition test is known as an évaluation System of cognitive function utilizing properties of animal to willingly explore a new object (Behavioural Brain Research 31, p.47 (1988)). An animal is placed in an apparatus containing two identical objects and allowed to freely explore (acquisition trial), after which one of the objects in the apparatus is changed to one having a different shape (novel object) and the animal is allowed to freely explore (test trial). When the animal remembers the shape of the object presented in the acquisition trial, it shows the property to explore the novel object for a longer time. In this test, such property is evaluated as an index of cognitive function. The médial prefrontal dopaminergic terminal-lesioned rat used in this test shows a decrease in the dopamine content and basal level of dopamine release of the media! prefrontal cortex, as well as working memory disorders, and is considered a model reflecting a décliné in the function of prefrontal cortex (Psychopharmacology, 230, p. 345 (2013)). [0040] <Preparation of animal model> CD(SD)IGS rat (male, Charles River) received Pentobarbital sodium sait (Tokyo Chemical Industry Co., Ltd., 30 mg/kg) intraperitoneally and fixed on a brain stereotaxis apparatus (SR-6, Narishige kagaku kikai kenkyusho) under anesthésia. Using a microinjection pump (CMA/100, Carnegie Medicine), dopaminergic neurotoxin, 6-hydroxidopamine hydrochloride (6-OHDA, Sigma-Aldrich) was injected over about 1 min at (1) 3.2 mm anterior, 0.8 mm left latéral and 3.0 mm ventral, (2) 3.2 mm anterior, 0.8 mm right latéral and 3.0 mm ventral, (3) 3.2 mm anterior, 0.8 mm left latéral and 5.0 mm ventral, (4) 3.2 mm anterior, 0.8 mm right latéral and 5.0 mm ventral, (5) 4.2 mm anterior, 0.8 mm left latéral and 4.0 mm ventral, and (6) 4.2 mm anterior, 0.8 mm right latéral and 4.0 mm ventral, each from the bregma suture of the rats to lésion dopaminergic terminais in the media! prefrontal cortex. 6-OHDA was prepared at a concentration of 4 pg/pL, injected at a flow rate of 1 pL/min over 1 min, and stood for 1 min. In the sham operated group, a stainless cannula was inserted into the same coordinates. In this case, to prevent lésion of noradrenergic neurons, desipramine hydrochloride (Sigma-Aldrich, 25 mg/kg) was intraperitoneally administered about 30 min before 6-OHDA injection. The dosing volumes of pentobarbital sodium and desipramine hydrochloride were calculated at 1 and 5 mL/kg based on the body weight measured on the administration day. The rats were used for the efficacy study after a recovery period of not less than 5 days postsurgery. CObject récognition test>
A yellow white apparatus with a circuler shape (diameter 82 cm, height 20 cm) was used. As the object, a brown glass bottle (diameter 5 cm, height 8 cm) and a gray agate mortar (diameter 8.5 cm, height 5 cm) were used. The two objects were placed in the apparatus at 20 cm from the wall. The apparatus and objects were used for each trial after cleaning with 50% éthanol.
To familiarize the rats with the expérimenter, they were handled for 3 days before the test. At 60 min before the test, compound (I) (suspended in 0.5 w/v% aqueous methylcellulose 400 (MC) solution and prepared to 0.5 mL per 100 g body weight of rats on the administration day) was orally administered at a dose of 0.3 mg/kg, or a vehicle (0.5 w/v% aqueous MC solution) free of the test compound was orally administered at 0.5 mL per
100 g body weight of rats on the administration day. Two identical objects were set in the apparatus, and the rats were placed therein, allowed to freely explore for 10 min (acquisition trial), and placed back in the home cage. Three 5 minutes later, an object having the same shape as that of the object presented in the acquisition trial (familier object) and an object having a different shape (novel object) were placed in the apparatus, and the rats were placed in the apparatus and allowed to freely explore for 3 min (test trial). The time spent in exploration (sniffing) each object of the rats in the test trial was measured, and the ratio (%) relative to the total exploration time was calculated. For data analysis, only the data of the rats having the total exploration time of not less than 5 seconds in the test trial were used.
<Results>
Table 1 shows the ratio of the familiar object and novel object exploration times relative to the total exploration time in mean ± standard error. For statistical analysis, statistical analysis software SAS (Release 9.1.3, SAS Institute 20 Inc.) was used. For comparison of the exploration time of the familiar object and the novel object, paired t-test was performed after confirmation of the normal distribution by a Shapiro-Wilk test. The level of statistical significance was set at p<0.05.
Table 1
Effect of compound (I) on exploration time
| group | surgery/administration | ratio (%) of exploration time | animal number (rats) | |
| familiar object | novel object | |||
| sham operated | sham operated /vehicle | 31.76 ± 3.98 | 68.24 ± 3.98 | 10 |
| vehicle administration | lesion/vehicle | 49.12 ± 3.53 | 50.88 ± 3.53 | 10 |
| compound (I) administration | lesion/compound (I) | 34.97 ± 2.88 | 65.03 ± 2.88 | 10 |
In Table, lésion means that surgery to lésion of dopaminergic !
terminais in the médial prefrontal cortex was performed.
In the sham operated group, the exploration time of the novel object was significantly longer than that of the familiar object (p<0.01). In the vehicle administration group, the exploration time was not different between them. In contrast, in the compound (I) administration group, the exploration time of the novel object was significantly longer than that of the familiar object (pCO.OOl).
By the above-mentioned test, compound (I) was confirmed to improve cognitive impairment due to a décliné in dopamine function in the médial prefrontal cortex.
That is, compound (I) or a pharmaceutically acceptable sait thereof is considered to be useful for the treatment and/or prophylaxis of frontal lobe dysfunction, for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease (for example, executive dysfunction, memory disorder (particularly short term memory disorder), impairment in visual spatial cognition, smell disturbance and the like), cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like.
[Experimental Example 2] Effect of compound (I) in an asynucleinopathy model
By reference to articles (Science, 338, p.949 (2012); Behavioral Brain Reexplore, 208, p.274 (2010)), an animal model capable of confirming a treatment and/or prophylactic effect on α-synucleinopathy, for example, Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) is generated.
An appropriate dose of a solution of ot-synuclein (rPeptide, S-100) or NAC61-95 (custom, Sigma) dissolved in phosphate buffered saline (PBS) is injected to the striatum or J latéral cérébral ventricle of SLC: ICR male mice to induce j i 15
18659 | cognitive impairment and/or movement disorder. After confirmation of the pathology induction, an appropriate dose of compound (I) is administered to the mice. Improvement of the pathology of the mice in a few hours after the administration is confirmed by behavioral pharmacological évaluation such as Y-maze, amount of spontaneous motor activity, CATWALK and the like.
From the above-mentioned test, compound (I) can be confirmed to hâve a treatment and/or prophylactic effect on asynucleinopathy, for example, Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like. [Experimental Example 3] Effect of compound (I) in an asynucleinopathy model
By reference to articles (Science, 338, p.949 (2012);
Behavioral Brain Reexplore, 208, p.274 (2010)), an animal model capable of confirming a treatment and/or prophylactic effect on oi-synucleinopathy, for example, Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder :
associated with Lewy body disease and the like) was generated .
as follows. (
The cognitive function was evaluated using a spontaneous alternation task. The spontaneous alternation task is known as an évaluation System of cognitive function utilizing properties of animal to willingly explore a novel environment (Neuroscience and Biobehavioral Reviews 28, p. 497 (2004)). That is, if the animal remembers the arm previously entered in exploration in a Y-maze apparatus, the behavior of spontaneous entry into a different arm is expressed by an alternation behavior rate, and used as an index of cognitive function. The motor function was evaluated by analyzing gait function in natural walk conditions using a gait analysis System. <Preparation of animal model>
I 16 ’
I ί ]
NAC61-95 (custom, Sigma) was dissolved in ΡΒΞ to préparé pg/pL NAC61-95 solution.
Under pentobarbital {Somnopentyl, Kyoritsuseiyaku, 50 mg/kg, i.p.) anesthésia, 5 pL of NAC61-95 solution was injected using a Hamilton syringe (10 pL) equipped with a double needle (27G, needle length 3 mm) into the right latéral cérébral ventricle of Slc:ICR mice (male, Japan SLC) over about 1 min, and stood for 1 min to induce cognitive impairment and/or movement disorder. The sham treatment group was injected with pL of ΡΒΞ.
<Spontaneous alternation task: évaluation of cognitive function>
Y-maze apparatus wherein three arms made of a black acrylic wall (height 20 cm, length 25 cm, width 5 cm) are each connected at 120 degree angle was used.
Mice were brought into the experiment room on the previous day of test for habituation. Mice were placed at the tip of any of the arms of the Y-maze apparatus and allowed to freely explore in the maze for 7 min. Entry of ail four limbs of a mouse into one arm was defined as entry into arm, and the order of entry of the mice into the arm was recorded. A behavior of continuous entry into ail three different arms was defined as spontaneous alternation behavior, and the percentage of alternation behavior was calculated by the following calculation formula.
number of spontaneous alternation behaviors Alternation behavior (%) = ’ “ x100 ( total arm entries ) - 2
For calculation of the alternation behavior, only the data of mice with not less than 10 total arm entries was used. <Gait analysis: évaluation of motor function>
A gait analysis System (CatWalk XT, ver.9.1, Noldus) was used. The System was constituted of a walkway with pressure dépendent luminescence glass and a light source, luminescence ceiling, highly sensitive highspeed caméra and analysis software, and the gait was analyzed by digitizing the brightness of the light emitted by the pressure dépendent luminescence glass in response to the pressure. The gait data was automatically recorded and analyzed by the analysis · 5 software only when the mice moved straight forward without stopping in the predetermined area on the walkway.
The mice were brought into the experiment room without light and habituated for not less than 1 hr. The mice were placed in the apparatus, and allowed to walk freely until 6 ίο running data were obtained for each mouse. The earliest three analyzable running data were used, and mean was calculated. By reference to an article relating to movement disorder in Parkinson's disease animal model (Journal of Biomédical Science 17, p. 9 (2010)), a decrease in the maximum contact area (Total 15 surface area of certain paw at the moment of maximum paw contact) and print area (total surface area of the paw print), as well as change in the gait pattern (sequence of contact of 4 paws) were used as indices of movement disorder.
<Drug treatment>
At 60 min before the test, compound (I) (suspended in 0.5 w/v% aqueous MC solution, and prepared to 0.5 mL per 100 g body weight of mouse on the administration day) was orally administered at a dose of 0.1 mg/kg, or a vehicle (0.5 w/v% aqueous MC solution) free of the test compound was orally administered at 0.5 mL per 100 g body weight of mice on the administration day.
<Results>
Table 2 shows the alternation behavior in the spontaneous alternation task in mean ± standard error. For statistical 30 analysis, statistical analysis software SAS (Release 9.2, SAS Institute Inc.) was used. For comparison of the two groups, homoscedasticity was assumed from the results of F-test, and Student's t-test was performed. The level of statistical significance was set at p<0.05.
Table 2
Effect of compound (I) on alternation behavior
| group | treatment/administration | alternation behavior (%) | animal number (mice) |
| sham treatment | ; ’ . vehicle/vehicle | 66.5 ± 1.6 | 16 |
| vehicle administration | NAC61-95/vehicle | 59.6 ± 1.6 | 16 |
| compound (I) administration | NAC61-95/compound (I) | 69.5 ± 2.4 | 16 |
The vehicle administration group showed a significantly low alternation behavior as compared to the sham treatment group (p<0.01), and cognitive impairment was induced by NAC6195 treatment. In contrast, the compound (I) administration group showed a significantly high alternation behavior as compared to the vehicle administration group (pCO.Ol), and improvement of cognitive impairment by NAC61-95 treatment was 10 found.
Table 3 shows each gait parameter in the gait test in mean ± standard error.
Table 3
Effect of compound (I) on gait parameters
| Group | sham treatment | vehicle administration | compound ( I) administration | |
| treatment/ administration | vehicle/ vehicle | NAC6195/vehicle | NAC61-95/ compound (I) | |
| animal number (mice) | 16 | 16 | 16 | |
| maximum contact area | right forepaw | 0.32 ± 0.03 | 0.24 ± 0.02 | 0.29 ± 0.02 |
| right hindpaw | 0.33 ± 0.03 | 0.27 ± 0.02 | 0.30 ± 0.02 | |
| Left forepaw | 0.31 ± 0.02 | 0.26 ± 0.02 | 0,30 ± 0.02 | |
| Left hindpaw | 0.31 ± 0.02 | 0.24 + 0.02 | 0.31 ± 0.02 | |
| print area | Right forepaw | 0.43 ± 0.04 | 0.33 ± 0.02 | 0.39 ± 0.02 |
| Right hindpaw | 0.41 ± 0.03 | 0.34 ± 0.03 | 0.37 ± 0.03 | |
| left forepaw | 0.42 ± 0.03 | 0.36 ± 0.03 | 0.40 ± 0.02 | |
| left | 0.39 ± 0.03 | 0.29 ± 0.03 | 0.38 ± 0.03 |
| hindpaw | ||||
| gait pattern | AA | 0.00 ± 0.00 | 2.79 ± 2.36 | 0.00 ± 0.00 |
| AB | 89.91 ± 3.36 | 74.11 ± 8.85 | 81.86 ± 4.25 | |
| CA | 4.18 ± 2.10 | 5.84 ± 2.45 | 13.39 ± 4.00 | |
| CB | 5.91 ± 2.30 | 17.26 ± 6.92 | 4.75 ± 1.79 |
AA; right forepaw -Wright hindpaw —>left forepaw —>left hindpaw
AB: right forepaw ->left hindpaw —>left forepaw —>right hindpaw
CA: right forepaw —>left forepaw —>right hindpaw —>left hindpaw
CB: right forepaw —>left hindpaw —>right hindpaw ->left forepaw
The vehicle administration group showed a significantly small maximum contact area and gait area of the right forepaw and left hindpaw as compared to the sham treatment group (both p<0.05), change in the gait pattern (decrease in pattern AB, 10 increase in pattern CB), and movement disorder was induced by
NAC61-95 treatment. In contrast, the compound (I) administration group showed a significantly large maximum contact area and gait area of the left hindpaw as compared to the vehicle administration group (p<0.05), tendency of the maximum contact area and gait area of the right forepaw being large (p<0.1), and the gait pattern with an increase in pattern AB and a decrease in pattern CB. From the above, improvement of movement disorder induced by NAC61-95 treatment was found in the compound (I) administration group.
From the above-mentioned test, compound (I) could be confirmed to hâve a treatment and/or prophylactic effect on otsynucleinopathy, for example, Lewy body disease (for example, cognitive impairment in Parkinson'’s disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like.
While compound (I) or a pharmaceutically acceptable sait thereof can be directly administered singly, it is generally desirably provided as various pharmaceutical préparations.
Such pharmaceutical préparations are used for animais or human. 30 The pharmaceutical préparation of the présent invention can contain compound (I) or a pharmaceutically acceptable sait thereof singly as an active ingrédient or as a mixture with any other active ingrédients. In addition, such pharmaceutical préparations are produced by mixing the active ingrédient with one or more kinds of pharmaceutically acceptable carriers (for 5 example, diluent, solvent, excipient and the like), and according to any method well known in the technical field of drug formulation study.
As an administration route, a route most effective for the treatment is desirably used, which may be oral or parentéral, for example, intravenous, transdermal and the like. Examples of the administration form include tablet, injection, external préparation and the like.
A form suitable for oral administration, for example, tablet and the like, can be produced using excipient such as 15 lactose and the like, disintegrant such as starch and the like, lubricant such as magnésium stéarate and the like, binder such as hydroxypropylcellulose and the like, and the like.
A form suitable for parentéral administration, for example, injection and the like can be produced using a diluent 20 or solvent such as sait solution, glucose solution, a mixture of sait water and glucose solution, and the like, and the like.
While a dosage form suitable for external préparation is not particularly limited, for example, ointment, cream, Uniment, lotion, cataplasm, plaster, tape and the like can be 25 mentioned. For example, ointment, cream and the like can be produced by, for example, dissolving or mixing and dispersing the active ingrédient in a base such as white petrolatum and the like.
The dose and administration frequency of compound (I) or 30 a pharmaceutically acceptable sait thereof vary depending on the administration form, âge and body weight of patients, nature or severity of the symptom to be treated and the like. In the case of oral route, 0.01 - 1000 mg, preferably 0.05 100 mg, is generally administered to an adult once to several 35 times per day. In the case of parentéral administration such as intravenous administration and the like, 0.001 - 1000 mg, preferably 0.01 - 100 mg, is generally administered to an adult once to several times per day. In the case of transdermal administration, an external préparation containing 0.001 - 10% of compound (I) or a pharmaceutically acceptable sait thereof is generally administered by applying once to several times. However, such dose and administration frequency vary depending on the aforementioned varions conditions.
The présent invention is explained in more detail in the following by referring to Examples, which are not to be construed as limitative. Examples [Example 1]
A tablet having the following composition is prepared by a conventional method. Compound (I) (40 g), lactose (286.8 g) and potatostarch (60 g) are mixed, and 10% aqueous solution (120 g) of hydroxypropylcellulose is added thereto. The mixture is kneaded, granulated, dried, and sieved to give granules for tableting by a conventional method. The granules are mixed with magnésium stéarate (1.2 g) and the mixture is tableted by a tableting machine with a 8 mm punch (manufactured by Kikusui, RT-15) to give tablets (containing 20 mg of active ingrédient per tablet).
Table 4
Formulation compound (I) 20mg lactose 143.4 mg potato starch 30mg hydroxypropylcellulose 6mg magnésium stéarate 0.6 mg
200 mg [Example 2]
An injection having the following composition is prepared by a conventional method. Compound (I) (1 g) is mixed with injectable distilled water, pH is adjusted to 7 by adding hydrochloric acid and aqueous sodium hydroxide solution, and injectable distilled water is added to make the total amount 1000 mL. The obtained mixture is aseptically filled in a glass vial by 2 mL to give injections (containing 2 mg of active ingrédient per vial).
Table 5
Formulation compound (I) 2 mg hydrochloric acid q.s.
aqueous sodium hydroxide solution q.s.
injectable distilled water g. s.
2.00 mL
[Reference Example 1]
Compound (I) was obtained according to the method described in Example 504 of WO 2005/063743.
Industrial Applicability
The présent invention can be utilized for the treatment and/or prophylaxis of, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease (for example, executive dysfunction, memory disorder (particularly short term memory disorder), impairment in visual spatial cognition, smell disturbance and the like), cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like.
This application is based on a patent application No. 2015-55532 filed in Japan, the contents of which are incorporated in full herein.
Claims (17)
- Claims1. A therapeutic and/or prophylactic agent for frontal lobe dysfunction, comprising a compound represented by the formula (D :(l) or a pharmaceutically acceptable sait thereof, as an active ingrédient.
- 2. The agent according to claim 1, wherein the frontal lobe dysfunction is cognitive impairment.
- 3. The agent according to claim 2, wherein the cognitive impairment is cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy or frontotemporal dementia.
- 4. The agent according to claim 2, wherein the cognitive impairment is cognitive impairment in Parkinson's disease.
- 5. The agent according to claim 4, wherein the cognitive impairment in Parkinson's disease is executive dysfunction, memory disorder, impairment in visual spatial cognition or smell disturbance.
- 6. The agent according to claim 2, wherein the cognitive impairment is cognitive impairment caused by chronic stress.
- 7. The agent according to claim 2, wherein the cognitive impairment is dementia with lewy bodies.
- 8. The agent according to claim 1, wherein the frontal lobe dysfunction is cognitive impairment due to a décliné in dopamine function in the médial prefrontal cortex. .
- 9. A therapeutic and/or prophylactic agent for Lewy body disease, comprising a compound represented by the formula (I):(l) or a pharmaceutically acceptable sait thereof, as an active ingrédient.
- 10. The agent according to claim 9, wherein the Lewy body disease is cognitive impairment in Parkinson's disease.
- 11. The agent according to claim 9, wherein the Lewy body disease is diffuse Lewy body disease.
- 12. The agent according to claim 9, wherein the Lewy body disease is dementia with lewy bodies.
- 13. The agent according to claim 9, wherein the Lewy body disease is movement disorder associated with Lewy body disease.
- 14. A compound represented by the formula (I):(l) or a pharmaceutically acceptable sait thereof, for use in the treatment and/or prophylaxis of frontal lobe dysfunction.
- 15. A compound represented by the formula (I):Λ9(D or a pharmaceutically acceptable sait thereof, for use in the 5 treatment and/or prophylaxis of Lewy body disease.
- 16. Use of a compound represented by the formula (I) :(I) or a pharmaceutically acceptable sait thereof, for the10 manufacture of a therapeutic and/or prophylactic agent for frontal lobe dysfunction.
- 17. Use of a compound represented by the formula (I):zYVN9 I B />“NH /==\Vy's ')-ch3 δ ο (D15 or a pharmaceutically acceptable sait thereof, for the manufacture of a therapeutic and/or prophylactic agent for Lewy body disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-055532 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA18659A true OA18659A (en) | 2019-04-08 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sebastianutto et al. | Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists | |
| EP2838530B1 (en) | Methods for treating parkinson's disease | |
| JP2018090566A (en) | Combination of EGFR T790M inhibitor and CDK inhibitor for the treatment of non-small cell lung cancer | |
| JP4705717B2 (en) | Use of NMDA antagonists with a certain affinity as antidepressants | |
| JP4867123B2 (en) | Neuropathic pain therapeutic agent and animal model of neuropathic pain | |
| JP2022501417A (en) | How to Treat Sensitive Cough or Itching with Ion Channel Inhibiting Compounds | |
| US20210393606A1 (en) | Therapeutic agent for frontal lobe dysfunction | |
| JP5786714B2 (en) | Therapeutic or preventive agent for neuropathic pain | |
| JP7062804B2 (en) | Treatment and / or prophylaxis for Lewy body disease | |
| OA18659A (en) | Therapeutic Agent for Frontal Lobe Dysfunction. | |
| EP1559447A1 (en) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism | |
| JPH09500375A (en) | Use of efaroxan and its derivatives for the manufacture of a medicament for the treatment of Parkinson's disease | |
| WO2018159716A1 (en) | Therapeutic agent for alcohol use disorders | |
| CN116419751A (en) | Application of bilobalide or bilobalide composition in preparing sedative medicine |